Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 200 Neoplasms 116 Breast Neoplasms 112 Colorectal Neoplasms 97 Ovarian Neoplasms 78 Prostatic Neoplasms 75 Neoplasm Metastasis 74 Lung Neoplasms 66 Multiple Myeloma 64 Squamous Cell Carcinoma of Head and Neck 49 Pancreatic Neoplasms 48 Endometrial Neoplasms 48 Recurrence 46 Stomach Neoplasms 39 Carcinoma, Renal Cell 39 Small Cell Lung Carcinoma 38 Melanoma 38 Leukemia, Lymphocytic, Chronic, B-Cell 38 Leukemia, Myeloid, Acute 34 Lymphoma, Non-Hodgkin 30 Urinary Bladder Neoplasms 29 Parkinson Disease 4, Autosomal Dominant Lewy Body 29 Triple Negative Breast Neoplasms 28 Head and Neck Neoplasms 26 Carcinoma, Hepatocellular 26 Lymphoma, Large B-Cell, Diffuse 25 Lymphoma, Follicular 25 Esophageal Neoplasms 24 Advanced Solid Tumors 24 Lymphoma 23

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HR+/HER2- Breast Cancer × 30 days × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡